July 20, 2020
Longfellow Real Estate Partners has secured a 33,000-square-foot office lease with Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells for the treatment of cancer, at 100 CambridgePark in Cambridge.
Longfellow acquired the 609,000-square-foot CambridgePark office campus in 2017. Vor Biopharma will be the first biotech firm to occupy the property, which Longfellow will finish converting to lab space for biotechs, pharma companies and research institutions later this year. Over the next three years, Longfellow will bring online 65,000 square feet of lab space at the property, including 18,000 square feet by early 2021.
“Cambridge is one of the country’s key hubs for life sciences innovation and a critical market for Longfellow as we continue to expand our national portfolio,” said Jamie Peschel, co-founder and managing partner at Longfellow. “We’re encouraged by the continued strong demand we’ve seen in the region throughout the COVID-19 pandemic—a crisis that underscored our need to continue to invest in our communities and in life sciences—and we’re excited to have a future-focused company like Vor as the first life sciences tenant on the campus.”
For comments, questions or concerns, please contact David Cohen